Related Experiment Video

Updated: Aug 10, 2026

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

[Modern concepts on the pathogenesis and therapy of tuberculous meningitis]

S Nikolić1

  • 1Dr Kosta Todorovitsh, Institute of Infective and Tropical diseases, Clinical centre of Serbia, Belgrade.

Srpski Arhiv Za Celokupno Lekarstvo
|January 1, 1996
PubMed

Insights

Tuberculous meningitis arises from disseminated tuberculosis, not primary infection. A nine-month treatment regimen using multiple antituberculous drugs shows effective outcomes, comparable or superior to longer standard therapies.

Area of Science:

  • Infectious Diseases
  • Neurology
  • Microbiology

Context:

  • Tuberculous meningitis (TBM) is a severe form of extrapulmonary tuberculosis.
  • Pathogenesis involves hematogenous dissemination from an occult primary focus.
  • Subependymal tubercles can rupture, seeding mycobacteria into the cerebrospinal fluid.

Purpose:

  • To elucidate the pathogenetic mechanisms of tuberculous meningitis.
  • To review modern therapeutic recommendations for TBM.
  • To evaluate the efficacy of short-course intermittent therapy.

Summary:

  • TBM originates from disseminated infection, often from an unapparent primary site.
  • Rupture of subependymal tubercles into the subarachnoid space facilitates meningeal spread.
  • A nine-month treatment regimen, including initial daily multi-drug therapy followed by intermittent isoniazid and Rifadin, yields comparable or superior outcomes to prolonged standard treatments (18-24 months).

Impact:

  • Highlights the importance of recognizing TBM's secondary nature in diagnosis.
  • Supports the adoption of shorter, intermittent therapeutic regimens for TBM.
  • Offers a more effective and potentially less burdensome treatment strategy for TBM patients.

More Related Videos

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

Identification of Potential Anti-TB Candidates: A Step-by-Step Guide to Synthesis, MIC Determination, and Cytotoxicity Assessment in Mammalian Cells10:24

Identification of Potential Anti-TB Candidates: A Step-by-Step Guide to Synthesis, MIC Determination, and Cytotoxicity Assessment in Mammalian Cells

Published on: May 22, 2026

Related Concept Videos

Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Bacterial Meningitis I: Introduction01:22

Bacterial Meningitis I: Introduction

Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...